Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T Cell Therapy Engager ALETA-001

Aleta Biotherapeutics announced that the UK Medicines and Healthcare products Regulatory Agency has granted an Innovation Passport under the Innovative Licensing and Access Pathway for CAR T cell therapy Engager candidate ALETA-001 for the treatment of patients suffering from the B-cell malignancies.